World-first breakthrough for Thalassaemia

Cure the Future are pleased to announce that Prof Rasko & his team at RPA have been part of an international trial – in which gene therapy has been used to successfully treat patients with the inherited blood disorder Thalassaemia. Of 22 patients with severe symptoms treated, 15 no longer require blood transfusions…

Car-T Therapy trials to get $2m Cancer Council funding

In Australia, around 3,300 people are diagnosed with pancreatic cancer each year. This devastating cancer carries one of the lowest survival rates. Professor Rasko and his team are trialling a potential new treatment for pancreatic cancer known as CAR T-cell immunotherapy. This type of treatment involves taking a patient’s own immune cells, growing them in a highly specialised clinical laboratory, reprogramming them to attack only cancer cells, and then returning them to the patient.

Haemophilia Breakthrough

Cure The Future is proud to have supported researchers at Sydney’s RPA as part of an international team to have developed a gene therapy for the life-threatening blood disorder, haemophilia. The breakthrough, led by Professor John Rasko, is a major milestone in the quest to cure the bleeding disorder and to the possibility of treating over 4000 other genetically inherited diseases.

FDA Approves 2nd Car-T Therapy – for Adult Lymphoma

The U.S. Food and Drug Administration today approved a 2nd cell-based gene therapy, to treat adult patients with certain types of large B-cell lymphoma who have not responded to or who have relapsed after at least two other kinds of treatment. “Today marks another milestone in the development of a whole new scientific paradigm for the treatment of serious diseases” said FDA Commissioner Scott Gottlieb, M.D.